Status:
COMPLETED
Methylated DNA Detect in Paraneoplastic Syndrome of Nervous System
Lead Sponsor:
Peking University Third Hospital
Conditions:
Paraneoplastic Neurological Syndrome
Eligibility:
All Genders
18-75 years
Brief Summary
The purpose of this study is to verify whether the cell-free DNA of lung cancer in the blood can be used as a biomarker for early diagnosis and prognosis evaluation of patient with paraneoplastic synd...
Detailed Description
Paraneoplastic neurological syndrome (PNS) is a clinical syndrome that affects the central nervous system, peripheral nerves, neuromuscular junctions and muscles by the distant influence of the tumor....
Eligibility Criteria
Inclusion
- The agnogenic typical neurological syndromes (including encephalomyelitis, marginal encephalitis, subacute cerebellar degeneration, strabismus ocular clonic-myoclonus, subacute sensory neuron disease, Lambert-Eaton myasthenic syndrome, skin Myositis, etc.) patient who predisposed to a tumor.
- Pathologically confirmed as lung cancer or suggested as lung cancer patient by imaging (pulmonary CT/Positron Emission Tomography-CT), tumor biomarkers, anti-brain tissue antibodies, etc.
Exclusion
- Lacunar infarction
- Aortic atherosclerotic cerebral infarction
- Clear cardiogenic cerebral infarction
- Other related system diseases (arteritis, vascular dissection, migraine and vasospasm, etc.)
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2019
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04454853
Start Date
December 1 2017
End Date
July 1 2019
Last Update
July 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, China